Enspryng (satralizumab) / Roche  >>  Phase 3
Welcome,         Profile    Billing    Logout  

10 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Enspryng (satralizumab) / Roche
2020-004436-21: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Generalized Myasthenia Gravis

Ongoing
3
240
Europe
Satralizumab, RO5333787, Injection
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Generalized Myasthenia Gravis (gMG), Myasthenia gravis is a rare neuromuscular disorder that causes weakness in the skeletal muscles. Myasthenia gravis affecting multiple muscle groups throughout the body is called gMG., Diseases [C] - Nervous System Diseases [C10]
 
 
2021-001088-26: A Clinical, Imaging and Biomarker Study in Neuromyelitis Optica Spectrum Disorder (NMOSD) with Satralizumab as an Intervention Studio clinico, di imaging e sui biomarcatori condotto nel disturbo dello spettro della neuromielite ottica (NMOSD) con Satralizumab come intervento

Not yet recruiting
3
100
Europe
satralizumab, [RO5333787], Solution for injection/infusion in pre-filled syringe, Enspryng
F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Neuromyelitis Optica Spectrum Disorder (NMOSD) Disturbo dello spettro della neuromielite ottica (NMOSD), NMOSD,also known as Devic disease, is a disorder of the brain and spinal cord dominated by inflammation of the optic nerve(optic neuritis)and inflammation of the spinal cord (myelitis). NMOSD,noto anche come malattia di Devic,è un disturbo del cervello e del midollo spinale dominato da infiammazione del nervo ottico (neurite ottica) e dall'infiammazione del midollo spinale (mielite)., Diseases [C] - Nervous System Diseases [C10]
 
 
2019-004092-39: A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients with Aquaporin-4 (AQP4) Antibody Positive Neuromyelitis Optica Spectrum Disorder

Not yet recruiting
3
8
Europe
Satralizumab, Ro 533-3787/F01- 06, Solution for infusion in pre-filled syringe, Enspryng
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Neuromyelitis Optica Spectrum Disorder (NMOSD), NMOSD is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis)., Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04963270 / 2020-004436-21: A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Active, not recruiting
3
185
Europe, Canada, Japan, US, RoW
Satralizumab, Placebo
Hoffmann-La Roche, Chugai Pharmaceutical
Generalized Myasthenia Gravis
01/24
09/24
NCT04660539 / 2020-003413-35: A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Completed
3
119
Europe, Canada, Japan, US, RoW
satralizumab, Enspryng, azathioprine (AZA), non-investigational medicinal product (NIMP), mycophenolate mofetil (MMF), NIMP, oral corticosteroids
Hoffmann-La Roche
Neuromyelitis Optica Spectrum Disorder
05/24
05/24
NCT05987423: A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease

Recruiting
3
120
Europe, Japan, US, RoW
Satralizumab, Placebo
Hoffmann-La Roche
Thyroid Eye Disease, TED
03/25
05/26
SatraGO-2, NCT06106828: A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease

Recruiting
3
120
Europe, Canada, US, RoW
Satralizumab, Placebo
Hoffmann-La Roche
Thyroid Eye Disease
05/25
05/26
Cielo, NCT05503264 / 2021-002395-39: A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

Recruiting
3
152
Europe, Japan, US, RoW
Satralizumab, Placebo
Hoffmann-La Roche, Chugai Pharmaceutical Co.
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
06/25
12/27
Meteoroid, NCT05271409 / 2021-003192-34: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Hourglass Apr 2022 - Jun 2022 : First patient in for P3 METEOROID trial for myelin oligodendrocyte glycoprotein antibody-associated disease
Recruiting
3
152
Europe, Canada, Japan, US, RoW
Satralizumab, Placebo
Hoffmann-La Roche, Chugai Pharmaceutical
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
07/26
12/28
SAkuraSun, NCT05199688: A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Recruiting
3
8
Europe, US, RoW
Satralizumab
Hoffmann-La Roche
Neuromyelitis Optica Spectrum Disorder, NMOSD
03/27
09/29

Download Options